Acucela Inc

(AUCL)

By |

Profile

Acucela Inc was incorporated on April 1, 2002, a Washington corporation, is a clinical-stage biotechnology company. The Company is engaged in discovering & developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting individuals. The Company's segment includes pharmaceutical product development in Age-Related Macular Degeneration is a retinal disease that can cause patients to experience reduced central vision and irreversible loss of central vision in severe cases, exists in two forms, dry AMD and wet AMD. Glaucoma is a progressive optic neuropathy that leads to irreversible damage to retinal ganglion cells. The damage may direct to diminish visual function and blindness, especially when not adequately treated and Dry eye syndrome, is a chronic and potentially debilitating condition involving ocular surface damage and symptoms of irritation that result from a decline in the quality or quantity of tears. The Company promotes their products in North America, Asia, the Pacific, the Middle East and North Africa. The Company competes with other biotechnology companies in respect of existing drugs and therapies.

Contact Information

Website: www.acucela.com
Main Phone: +1 206 805-8300
Address: 1301 Second Avenue
Address 2: Suite 4200
State: WA
City / Town: Seattle
Country: USA
Postal Code: 98101

Issuer Information

Exchange: GREY
Employees: 49
NAICS: Pharmaceutical Preparation Manufacturing(325412)
(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 45.00 52 Wk Low 10.50
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 37,832,830.00 EPS (TTM) -0.96 PE Ratio N/A Exchange Greys